



Relection/Amndt B/7.18.02

PATENT

Docket No. 290.0010 0101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 16 2002
TECH CENTER 1600/2000

Applicant(s): Kinch et al.) Group Art Unit: 1642
Serial No.: 09/640,935) Examiner: M. Yu
Confirmation No.: 3254)
Filed: 17 August 2000)
For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER
(As Amended)

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The Office Action mailed 6 May 2002 has been received and carefully reviewed. Please enter the following amendment.

In the Claims

Please cancel claims 1-57, without prejudice.

Please add new claims 58-102. The new claims are provided below in clean form.

58. A method for treatment of a patient having a metastatic tumor, said tumor comprising a population of metastatic cells that express EphA2, said method comprising administering to the patient a therapeutically effective amount of an EphA2 agonist wherein said administration reduces metastasis.

59. The method of claim 58 wherein the metastatic cells overexpress EphA2 as compared to normal cells.

07/12/2002 SDENB0B1 00000100 09640935

01 FC:104

280.00 0P